Royal Bank Of Canada Satsuma Pharmaceuticals, Inc. Transaction History

Royal Bank Of Canada

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.59 - $4.3 $240 - $399	-93 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$3.78 - $5.32 $351 - $494	93 New	93 $0
Q3 2021 Nov 15, 2021	SELL	$4.54 - $7.17 $8,053 - $12,719	-1,774 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$4.8 - $7.25 $8,515 - $12,861	1,774 New	1,774 $13,000

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.